In summary, these new data suggest that immunosuppressive myeloid cells, and presumably MDSCs, suppress anti-tumor immunity by inhibiting antigen-specific T cell function in GBM, at least in part via TIGIT and PD1 pathways, which may have major implication to patient treatments by immunotherapy. Here, PDCD1 is linked to neoplasm.